FDA CENTER FOR DRUGS DIRECTOR WOODCOCK TAKES OFFICE MAY 23
This article was originally published in The Tan Sheet
Executive Summary
FDA CENTER FOR DRUGS DIRECTOR WOODCOCK TAKES OFFICE MAY 23 following clearance by HHS to assume the top spot at the center from acting Director Murray Lumpkin, MD. The appointment of Janet Woodcock, MD to head the Center for Drug Evaluation and Research comes almost four months after FDA Commissioner David Kessler nominated her for the CDER director slot in late January ("The Tan Sheet" Jan. 31, p. 6). In the interim, she continued as director of the Office of Therapeutics Research & Review in the Center for Biologics Evaluation & Research. Lumpkin will resume his role as CDER deputy director for review management.